2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1
2020
Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.
Charytan D, Hsu J, Mc Causland F, Waikar S, Ikizler T, Raj D, Landis J, Mehrotra R, Williams M, DiCarli M, Skali H, Kimmel P, Kliger A, Dember L, Himmelfarb J, Anderson A, Hung A, Sharma S, Weiner D. Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360 2020, 1: 1380-1389. PMID: 35372900, PMCID: PMC8815530, DOI: 10.34067/kid.0004342020.Peer-Reviewed Original ResearchConceptsIsosorbide dinitrateCoronary flow reserveAdverse eventsMaintenance HDMitral annular e' velocityDouble-blind pilot trialFlow reserveRecurrent intradialytic hypotensionRandomized to placeboMaximum tolerated doseTissue Doppler echocardiographyParticipants discontinued therapyGastrointestinal side effectsDetect between-group differencesPilot trialIntra-dialytic hypotensionPlacebo-ControlledPositron emission tomographyDose escalationHeart failure mortalityDose reductionStudy medicationTolerated dosePlacebo groupCombination therapy